Abstract: Objectiv To investigate the changes of serum and hepatic fibrinogen-like protein 2 （sFGL2） levels in patients with chronic hepatitis B（CHB） and hepatitis B cirrhosis after receiving entecavir therapy. Methods 112 patients with CHB and 112 patients with hepatitis B cirrhosis were admitted to our hospital between June 2016 and June 2017,and among patients with CHB were mild in 38 cases,moderate in 45 cases,and severe in 29 cases. All patients received liver biopsies and were given entecavir treatment for 72 weeks. Serum sFGL2 levels were assayed by ELISA,and hepatic sFGL2 expression was detected by immunohistochemistry. Results The positive rate of hepatic sFGL2 expression in patients with CHB was 63.4% （71/112）,much lower than 82.1% （92/112） in cirrhotic patients （P<0.05）;hepatic sFGL2 expression intensified as liver injuries increased in patients with CHB;at the end of 72 week observation,serum ALT,AST and sFGL2 levels in patients with CHB were （49.8±6.3） U/L,（52.3±7.6）U/L and （84.7±10.3） μg/L,while in patients with liver cirrhosis were （41.8±4.2）U/L,（42.3±5.4） U/L and（104.9±19.4） μg/L,respectively,and the difference was significant between the two groups （P<0.05）;at the end of 24 w,48 w and 72 w,serum sFGL2 level in patients with CHB were（98.2±10.8） μg/L,（81.6±9.5） μg/L and （69.4±8.7） μg/L,in a gradually decreased manner;at the end of 72 w,65 patients with CHB got complete response,31 got partial response and 16 were non-responders,and their serum sFGL2 levels were （74.6±9.1） μg/L,（97.2±11.4） μg/L and（123.6±15.2） μg/L,respectively,with the differences among the three groups significant（P<0.05）. Conclusion Serum and hepatic sFGL2 levels in patients with CHB significantly decrease after antiviral therapy,which might be closely related to the state of disease activity and the response to treatment.

Key words: Liver cirrhosis, Hepatitis B, Soluble fibrinogen-like protein 2, Entecavir, Therapy